We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reviews: Effects of Transdermal Rivastigmine on ADAS-Cog Items in Mild-to-Moderate Alzheimer’s Disease.
- Authors
Grossberg, George T.; Schmitt, Frederick A.; Xiangyi Meng; Tekin, Sibel; Olin, Jason
- Abstract
Alzheimer’s disease (AD) patients treated with rivastigmine transdermal patch have shown statistically significant differences versus placebo on the AD Assessment scale-cognitive subscale (ADAS-cog). In this retrospective analysis of a double-blind, placebo- and active-controlled, 24-week clinical trial, the specific effects of rivastigmine patch on individual ADAS-cog items and cognitive domains (memory, language, and praxis) were explored. The mean baseline to week 24 changes were calculated for each ADAS-cog item and domain in this exploratory, hypothesis-generating analysis. Patients on 9.5 mg/24 h rivastigmine patch, 17.4 mg/24 h rivastigmine patch, and 3 to 12 mg/d rivastigmine capsules showed improvements over placebo on the memory and praxis ADAS-cog subscales. The rivastigmine patch groups also showed improvements on the language subscale. Significant differences versus placebo were seen on several individual item scores in the rivastigmine-treated groups. Rivastigmine patch was associated with improvements on the memory, praxis, and language domains of cognition in patients with mild-to-moderate AD.
- Subjects
CHOLINESTERASE inhibitors; THERAPEUTIC use of transdermal medication; ALZHEIMER'S disease; ANALYSIS of covariance; ANALYSIS of variance; CLINICAL trials; PROBABILITY theory; RESEARCH funding; SCALE items; RETROSPECTIVE studies; DRUG therapy; THERAPEUTICS
- Publication
American Journal of Alzheimer's Disease & Other Dementias, 2010, Vol 25, Issue 8, p627
- ISSN
1533-3175
- Publication type
Article
- DOI
10.1177/1533317510385808